A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
A phase 1/2 trial of Furmonertinib and Carboplatin in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
Overview
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT07229599 by Minghui Pharmaceutical (Hangzhou) Ltd, with 300 participants planned, started 2025-05-09 and due to reach its primary completion in 2029-05. Interventions recorded: MHB036C for Injection, MHB039A for Injection, Furmonertinib and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Shares MHB036C, MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C for Advanced Solid Tumor
Shares MHB036C, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB039A for Advanced Solid Tumor
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Furmonertinib, Carboplatin and the tag pipeline.
- TrialA Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Shares Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Shares Furmonertinib and the tag pipeline.
- TrialTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Shares Furmonertinib and the tag pipeline.